MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer.
chemovirotherapy
cytosine deaminase
fluorouracil
measles virus
miR-148a
microRNAs
oncolytic viruses
pancreatic cancer
prodrugs
virotherapy
Journal
Molecular therapy oncolytics
ISSN: 2372-7705
Titre abrégé: Mol Ther Oncolytics
Pays: United States
ID NLM: 101666776
Informations de publication
Date de publication:
25 Jun 2021
25 Jun 2021
Historique:
received:
12
11
2020
accepted:
28
04
2021
entrez:
18
6
2021
pubmed:
19
6
2021
medline:
19
6
2021
Statut:
epublish
Résumé
Advanced pancreatic cancer is characterized by few treatment options and poor outcomes. Oncolytic virotherapy and chemotherapy involve complementary pharmacodynamics and could synergize to improve therapeutic efficacy. Likewise, multimodality treatment may cause additional toxicity, and new agents have to be safe. Balancing both aims, we generated an oncolytic measles virus for 5-fluorouracil-based chemovirotherapy of pancreatic cancer with enhanced tumor specificity through microRNA-regulated vector tropism. The resulting vector encodes a bacterial prodrug convertase, cytosine deaminase-uracil phosphoribosyl transferase, and carries synthetic miR-148a target sites in the viral
Identifiants
pubmed: 34141871
doi: 10.1016/j.omto.2021.04.015
pii: S2372-7705(21)00065-6
pmc: PMC8182383
doi:
Types de publication
Journal Article
Langues
eng
Pagination
340-355Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
G.U. is co-founder, stakeholder, and CMO/CSO of CanVirex AG, a company investigating oncolytic viruses as novel cancer immunotherapeutics. J.C.B. is co-founder, stakeholder, and co-director of Turnstone Biologics, a company developing viral immunotherapeutics against cancer. The remaining authors declare no competing interests.
Références
BMC Cancer. 2017 Aug 29;17(1):576
pubmed: 28851316
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
Mol Ther Oncolytics. 2015;2:
pubmed: 26640815
Cancer Res. 2003 Dec 1;63(23):8366-76
pubmed: 14678998
Cancer Gene Ther. 2018 Aug;25(7-8):184-195
pubmed: 29735994
Biotechniques. 2005 Feb;38(2):287-93
pubmed: 15727135
Nat Commun. 2019 Aug 8;10(1):3574
pubmed: 31395879
J Exp Clin Cancer Res. 2019 Jun 19;38(1):268
pubmed: 31217020
Nat Commun. 2017 Nov 9;8(1):1395
pubmed: 29123084
Sci Rep. 2020 Jan 15;10(1):337
pubmed: 31941932
Cancer Gene Ther. 2014 Sep;21(9):373-80
pubmed: 25145311
Nat Med. 2015 May;21(5):530-6
pubmed: 25894825
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
Cytokine Growth Factor Rev. 2020 Dec;56:28-38
pubmed: 32660751
EMBO J. 1995 Dec 1;14(23):5773-84
pubmed: 8846771
Nat Rev Immunol. 2020 Jan;20(1):25-39
pubmed: 31570880
Nat Rev Microbiol. 2008 Jul;6(7):529-40
pubmed: 18552863
Eur J Immunol. 2017 Dec;47(12):2026-2038
pubmed: 28880997
Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
Mol Ther. 2011 Jun;19(6):1097-106
pubmed: 21468006
Nature. 2011 Aug 31;477(7362):99-102
pubmed: 21886163
Cancer Gene Ther. 2011 Jun;18(6):435-43
pubmed: 21394109
J Virol. 1993 Oct;67(10):6025-32
pubmed: 8371352
Cancer Res. 2004 Jul 15;64(14):4919-26
pubmed: 15256464
Viruses. 2020 Feb 21;12(2):
pubmed: 32098134
Nat Rev Microbiol. 2014 Jan;12(1):23-34
pubmed: 24292552
J Clin Oncol. 2016 Aug 10;34(23):2784-96
pubmed: 27247222
Blood. 2004 Mar 1;103(5):1641-6
pubmed: 14604966
Cancer Gene Ther. 2012 Mar;19(3):181-91
pubmed: 22076043
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
Gynecol Oncol. 2013 Aug;130(2):362-8
pubmed: 23676551
Biomedicines. 2018 Nov 05;6(4):
pubmed: 30400571
Biometrics. 1990 Sep;46(3):673-87
pubmed: 2242409
Mol Ther Oncolytics. 2018 Apr 12;9:30-40
pubmed: 29988512
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Vaccine. 2013 Oct 1;31(42):4795-801
pubmed: 23948230
PLoS One. 2013 Aug 14;8(8):e70594
pubmed: 23967078
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
Clin Cancer Res. 2009 Jan 15;15(2):511-9
pubmed: 19147756
J Virol. 1999 Nov;73(11):9568-75
pubmed: 10516065
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Cancer Sci. 2016 Nov;107(11):1647-1652
pubmed: 27561180
Nat Biotechnol. 2008 Dec;26(12):1346-8
pubmed: 19060871
Cancer Res. 1985 Apr;45(4):1753-61
pubmed: 3978637
N Engl J Med. 2005 Feb 3;352(5):476-87
pubmed: 15689586
Lab Invest. 2011 Oct;91(10):1472-9
pubmed: 21709669
Nat Rev Gastroenterol Hepatol. 2020 Aug;17(8):487-505
pubmed: 32393771
Clin Cancer Res. 2018 May 1;24(9):2128-2137
pubmed: 29437789
Nat Genet. 2015 Oct;47(10):1168-78
pubmed: 26343385
Mol Ther Oncolytics. 2018 Dec 15;12:68-78
pubmed: 30705967
Gene Ther. 2008 Jul;15(14):1024-34
pubmed: 18356818
J Cancer. 2016 Jun 21;7(10):1233-41
pubmed: 27390598
Cancer Gene Ther. 2011 Aug;18(8):598-608
pubmed: 21701532
Oncogene. 2007 Jun 28;26(30):4442-52
pubmed: 17237814
Cancer Res. 2018 Oct 15;78(20):5992-6000
pubmed: 30115692
Nature. 2005 Jun 9;435(7043):834-8
pubmed: 15944708
Cancer Res. 2010 Apr 15;70(8):3052-61
pubmed: 20388795
Cancers (Basel). 2018 Sep 26;10(10):
pubmed: 30261620
J Virol. 2006 Jun;80(12):5708-15
pubmed: 16731909
Nat Struct Mol Biol. 2008 Jul;15(7):690-8
pubmed: 18596815
J Natl Cancer Inst. 2018 Oct 1;110(10):1123-1132
pubmed: 29788332
Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2909-14
pubmed: 21282607
Clin Chem. 2010 Jul;56(7):1107-18
pubmed: 20431052
Nat Med. 2011 Apr;17(4):500-3
pubmed: 21460848
Nat Rev Cancer. 2018 Jul;18(7):419-432
pubmed: 29695749
J Virol. 2008 Nov;82(22):11009-15
pubmed: 18799589
Hum Gene Ther. 2013 Jul;24(7):644-54
pubmed: 23642239
Hum Gene Ther. 1997 Jul 20;8(11):1395-401
pubmed: 9295134
Oncoimmunology. 2018 Aug 27;7(12):e1503032
pubmed: 30524901
Mol Ther. 2008 Aug;16(8):1437-43
pubmed: 18560417
Mol Cancer Ther. 2007 Apr;6(4):1186-97
pubmed: 17406031
J Gen Virol. 1987 Jun;68 ( Pt 6):1695-703
pubmed: 3585281
Cancer Gene Ther. 2020 Dec;27(12):910-922
pubmed: 32231231
Nat Med. 2008 Nov;14(11):1278-83
pubmed: 18953352
Viruses. 2019 Oct 03;11(10):
pubmed: 31623390
J Clin Oncol. 1997 Jun;15(6):2403-13
pubmed: 9196156
N Engl J Med. 2014 Nov 27;371(22):2140-1
pubmed: 25427123
Mol Ther. 2014 Nov;22(11):1949-59
pubmed: 25156126
Mol Immunol. 2003 Sep;40(2-4):109-23
pubmed: 12914817
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
Curr Cancer Drug Targets. 2018;18(2):177-187
pubmed: 28228086
Nat Rev Clin Oncol. 2014 Nov;11(11):630-2
pubmed: 25311350
J Virol. 1999 Jun;73(6):4823-8
pubmed: 10233943
Cancer Res. 2006 Aug 1;66(15):7694-700
pubmed: 16885371
J Invest Dermatol. 2013 Apr;133(4):1034-42
pubmed: 23223133
Cancer Res. 2007 Nov 15;67(22):10939-47
pubmed: 18006839
FEMS Microbiol Lett. 1998 Oct 1;167(1):41-9
pubmed: 9785450
Mol Ther. 2007 Sep;15(9):1600-6
pubmed: 17551507
Gut. 2019 Jun;68(6):1034-1043
pubmed: 30658994
Nature. 2011 Nov 02;480(7378):530-3
pubmed: 22048310
N Engl J Med. 2018 Jul 12;379(2):150-161
pubmed: 29943666
Oncoimmunology. 2017 Jan 31;6(4):e1285992
pubmed: 28507792
J Clin Oncol. 2019 Oct 10;37(29):2592-2600
pubmed: 31356140
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
Int J Oncol. 2019 Aug;55(2):347-358
pubmed: 31268165